In silico evaluation of Marchantin C as a potential alpha-glucosidase inhibitor for diabetes and obesity with molecular docking and ADMET profiling
Year: 2026
Type: article
Abstract: Metabolic disorders, such as obesity and diabetes, necessitate the discovery of novel and effective enzyme inhibitors. Alpha-glucosidase is a therapeutic target for controlling postprandial hyperglycemia. The inhibition potential of Marchantin C, was evaluated against human intestinal α-glucosidase using integrated in silico approaches in this study. Molecular docking simulations performed via AutoDock Vina revealed that Marchantin C possesses an exceptional binding affinity of -8.6 kcal/mol, significantly outperforming the clinical reference drugs acarbose (-6.3 kcal/mol) and miglitol (-5.0 kcal/mol). Notably, the binding energy of Marchantin C was also superior to the native-fixed pose of acarbose (-7.8 kcal/mol), confirming its high thermodynamic stability within the catalytic pocket. Interaction analysis demonstrated that Marchantin C effectively targets the enzyme's catalytic centre, forming crucial bonds with residues Asp203 and Thr205, supplemented by Pi-Pi stacking with Trp406. Furthermore, ADMET and pharmacokinetic profiling via SwissADME indicated that Marchantin C exhibits high gastrointestinal absorption and a favourable drug-likeness profile, adhering to Lipinski's Rule of Five. Visualisation through BOILED-Egg and bioavailability radar plots further supported its potential as an orally active agent. These findings provide strong computational evidence that Marchantin C is a promising natural lead compound for managing obesity and type 2 diabetes, warranting further in vivo investigations.
Source: Anatolian Bryology
Author: Ergin Murat Altuner
Institution: Kastamonu University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7225993379
